SOX2 and neoplasm: demonstrated that in melanoma, colon and pancreatic cancers, blocking CDK1 expression reduced the phosphorylation, localisation and transcriptional activity of the pluripotency‐associated transcription factor SOX2, thereby inhibiting tumour initiation.26